Navigation Links
Northwest Secures US$1.0 Million Debt Financing
Date:10/1/2008

chnology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at http://www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning the Company's plans to move its programs forward, statements regarding the Company's clinical trials and other business development activities, and statements regarding its fundraising activities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks and uncertainties regarding the Company's ability to secure additional financing or raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings, including in the Risk Factors section of the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and in its recently filed Form S-1. Finally, there may be other factors not mentioned above or included in the Company's SEC filings or recently filed Form S-1 that may cause actual results to differ materially from those projected in any forward-looking s
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Northwestern chemists take gold, mass-produce Beijing Olympic logo
2. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
3. Northwestern chemist investigates lost reds in Homer painting
4. Nikon Instruments Opens New Imaging Center at Northwestern University
5. Northwest Secures US$4.0 Million in Debt Financing
6. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
7. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
8. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
9. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
10. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
11. Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
(Date:4/30/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) a ... biosimilar therapeutics including high value and difficult to ... previously announced underwritten public offering of 6,750,000 shares ... price of $15.50 per share. This includes the ... option to purchase up to 750,000 additional shares ...
(Date:4/30/2015)... Available in select spas in ... , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield Cream provides ... battling the weakening threat of inflammaging, aging directly ... with star ingredient GLYCOSEA, a complex of restructuring ... of soothing minerals and trace elements. GLYCOSEA works ...
(Date:4/29/2015)... Washington, and BALTIMORE, Maryland, USA (PRWEB) April 29, 2015 ... event for photonics, optical sensing, and imaging on the ... place for government program managers, researchers, applications developers, and ... technology of sensing and imaging for multiple applications. , ... defense and security, and commercial and scientific sensing and ...
Breaking Biology Technology:Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4
... Virobay, Inc., a privately held ... protease inhibitors for the treatment of autoimmune diseases, ... showing that one of the company,s spectrum-selective cathepsin ... bone cancer pain.  Virobay has a series of ...
... 14, 2011 A new retrospective ... etexilate mesylate) capsules 150mg twice daily reduced the ... warfarin in patients with non-valvular atrial fibrillation (NVAF) ... (sHF), with no significant interaction for major bleeding ...
... inVentiv Health, Inc., offering best-in-class clinical, commercial ... today that it has been selected by the ... operations support, as well as recruiting and sales ... for Type 2 diabetes. inVentiv ...
Cached Biology Technology:Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model 2Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model 3New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 2New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 3New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 4New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 5New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 6New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 7New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation 8inVentiv Health Selected to Provide Sales Operations Support for Santarus 2inVentiv Health Selected to Provide Sales Operations Support for Santarus 3inVentiv Health Selected to Provide Sales Operations Support for Santarus 4
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... issued today, co-authored by the Wildlife Conservation Society (WCS) ... the 25 most endangered turtle species from around the ... five individuals. Decimated by illegal hunting for both ... many turtle species will go extinct in the next ...
... in cancer treatment, destroy not only cancer cells but ... Consequently, after surviving cancer many female patients are confronted ... relationship between infertility and chemotherapeutic agents has been assumed, ... , Scientists from the research group of Prof. Volker ...
... Calif. and STATE COLLEGE, Pa., Feb. 22, 2011 ... GeneMarker HID forensics software will power the data analysis ... for human identification. The incorporated software will enable the ... standardized formats compatible with human identification database search systems. ...
Cached Biology News:Shellshock: New report lists 25 most endangered turtle species 2Why chemotherapy causes more infertility in women than in men 2Why chemotherapy causes more infertility in women than in men 3SoftGenetics to Supply Forensic Analysis Software for IntegenX's Automated DNA Identity Profiling System 2SoftGenetics to Supply Forensic Analysis Software for IntegenX's Automated DNA Identity Profiling System 3
... performance agitation and temperature control for microbiology ... wells independently and is suitable for DASGIP ... working volume. Its temperature ranges from approximately ... well is equipped with an individual electrical ...
... analyzes and reports the data from any one ... a chart recorder. The final data is sent ... end-point selection is automatic for Systolic, Mean, Heart ... The user is always in the position to ...
... DNA microarrays designed for your specific applications ... Paraflo microfluidic synthesis platform. Thousands of customer ... LC Sciences can provide assistance with custom ... part of our comprehensive Custom DNA Microarray ...
... RNA aptamer screening and binding optimization and ... microfluidic on-chip synthesis platform. These microarrays are ... Aptamer Microarray Service. Probe Content ... contains greater than 1500 known aptamer sequences. ...
Biology Products: